Table 8.

Results of PCP Salvage Reirradiation.

Author	Number of Patients	Years of Treatment	TD (Gy)	Equipment Used	Percent Receiving ADT	Median FU (Months)	Endpoint	Results (%)
Zilli et al 19	14a	2003-2008	44-72 + 18-25h	Unspecified	79	94	5 years bDFS	35.7
Vavassori et al 20	6b	2007-2008	30	CyberKnife	60	11.2	bDFS	40
Zerini et al 21	32c	2008-2013	25-30	Saturno 43, Clinac 600, Clinac 2100, RapidArc, Vero, CyberKnife	34	21.3	NED	40.6
Fuller et al 22	29d	2009-2014	34	CyberKnife	0	24	2 years bDFS	82
Janoray23	11e	2011-2014	36.25	CyberKnife	9	11.7	1 year bDFS	85.7
Mbeutcha24	18f	2011-2015	35	CyberKnife	55.6	14.5	bNED	55.6
Miszczyk et al	38g	2012-2017	18-36.25	CyberKnife	55.3	14.4	NED LC	68.4 86.8

Abbreviations: ADT, androgen deprivation therapy; bDFS, biological disease-free survival; LC, local control; FU, follow-up; NED, non-evidence of disease; PCP, prostate cancer patients; TD, total dose.

^aModalities of treatment used during prior treatment: 12 EBRT, 2 EBRT + BT boost.

^bModalities of treatment used during prior treatment: 6 EBRT.

^cModalities of treatment used during prior treatment: 10 RT, 22 RP + RT, including 29 cases of EBRT and 3 cases of BT.

^dModalities of treatment used during prior treatment: 28 EBRT, 1 ¹²⁵I BT.

^eModalities of treatment used during prior treatment: 11 EBRT.

^fModalities of treatment used during prior treatment: 18 EBRT.

^gModalities of treatment used during prior treatment: 34 EBRT, 1 BT, 3 EBRT + BT boost.

^fBT/CK boost.